Director Dealing

Bioventix plc                                 

                        ("Bioventix" or the "Company")                         

                               Director dealing                                

Bioventix plc (AIM: BVXP) was notified on 16 April 2015 that on the same day,
due to institutional investor demand, the following director dealt in the
ordinary shares of 5 pence each ("Ordinary Shares") in the Company:

Name        Position     Type of      Number of    Price    Ordinary  Percentage
                         transaction   Ordinary      per  shares and of Ordinary
                                         Shares Ordinary      voting  Shares and
                                                   Share rights held      voting
                                                 (pence)   following rights held
                                                                 the   following
                                                         transaction         the
                                                                     transaction
                                                                                
Peter       Chief        Disposal      100,000*      800     661,176       13.1%
Harrison    Executive                                                           

*    3,000 of which were held in the name of his wife          


For further information please contact:

Bioventix plc              Chief Executive Officer    Tel: [phone]       
Peter Harrison                                                                 
                                                                               
finnCap Ltd                Corporate Finance          Tel: [phone]       
Geoff Nash/Simon Hicks     Corporate Broking                                   
Steve Norcross                                                             
    

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.